After that, eligibility is based mainly on body weight and health status
adults had already taken GLP-1 at some point and the global market is projected to triple in the next five years, driven by high and rising levels of type-2 diabetes and obesity, aging populations, urbanization and public health initiatives: (2018-2030E) Global pharmaceutical companies dominate todays production: With ~300 clinical trials around the world, research continues into applications to other metabolic disorders, cardiovascular and kidney disease and neurological conditions
Moreover, it is characterized by a high prevalence of coexistence with many other diseases including metabolic disorders such as type 2 diabetes mellitus (T2DM) and obesity
Eric Perakslis Hear directly from our Chief Science Officer about how Shotsy is built on a foundation of science, safety, and data privacy
Only 10% said they would make no trade-offs at all
As generic and compounded versions of GLP-1 medications become more available and brand-name prices potentially decrease, insurance companies will face less financial incentive to maintain restrictive BMI thresholds